Skip to main content
. 2013 Mar 23;12:48. doi: 10.1186/1475-2840-12-48

Table 2.

Baseline demographics

 
 DURATION-4*
 DURATION-2†
 DURATION-3‡
  ExQW Met Sita Pio EQW Sita Pio ExQW IG
N
 248
 246
 163
 163
 160
 166
 165
 233
 223
Sex (Male) (%)
 56
 63
 58
 60
 56
 52
 48
 52
 55
Race (%)
  
  
  
  
  
  
  
  
  
 American Indian or Alaska Native
 <1
 1
 1
 0
 0
 2
 0
 0
 0
 Asian
 22
 21
 20
 21
 23
 25
 24
 6
 6
 Black or African American
 3
 5
 2
 3
 12
 12
 8
 1
 >1
 Hispanic
 7
 9
 8
 9
 31
 30
 27
 12
 9
 Other
 0
 <1
 0
 0
 1
 1
 2
 0
 0
 White
 68
 65
 69
 68
 33
 30
 39
 82
 85
Age (y)
 54 ± 11
 54 ± 11
 52 ± 11
 55 ± 11
 52 ± 10
 52 ± 11
 53 ± 10
 58 ± 10
 58 ± 9
Duration of diabetes (y)
 3 ± 3
 3 ± 4
 3 ± 4
 3 ± 4
 6 ± 5
 5 ± 5
 6 ± 6
 8 ± 6
 8 ± 6
Baseline weight (kg)
 87 ± 19
 86 ± 20
 89 ± 19
 86 ± 18
 89 ± 20
 87 ± 20
 88 ± 21
 91 ± 19
 91 ± 16
Baseline BMI (kg/m2)
 31 ± 5
 31 ± 5
 32 ± 5
 31 ± 5
 32 ± 5
 32 ± 5
 33 ± 6
 32 ± 5
 32 ± 5
Baseline HbA1c (%)
 8.5 ± 1.2
 8.6 ± 1.2
 8.5 ± 1.3
 8.5 ± 1.2
 8.6 ± 1.2
 8.5 ± 1.2
 8.5 ± 1.1
 8.3 ± 1.1
 8.3 ± 1.0
Baseline FBG (mmol/L)
 9.9 ± 2.9
 10.0 ± 3.4
 9.7 ± 2.6
 9.8 ± 3.0
 9.2 ± 2.9
 9.1 ± 2.5
 9.1 ± 2.4
 9.9 ± 2.5
 9.7 ± 2.7
Baseline SBP (mm Hg)
 129 ± 12
 129 ± 15
 130 ± 13
 131 ± 15
 126 ± 14
 126 ± 14
 127 ± 14
 135 ± 17
 133 ± 16
Baseline LDL (mmol/dL)
 3.1 ± 1.1
 2.9 ± 0.9
 3.0 ± 0.9
 3.1± 1.0
 2.6 ± 0.8
 2.8 ± 0.9
 2.9 ± 1.0
 2.7 ± 0.9
 2.7 ± 0.9
Background therapy (n)
  
  
  
  
  
  
  
  
  
 Metformin
  
  
  
  
 160
 166
 165
 164
 157
 Diet and Exercise
 248
 246
 163
 163
  
  
  
  
  
 Metformin + Sulfonylurea               69 66

*†‡Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once-Weekly-4, -2, -3 [23-25].

Values are shown as mean ± SD.

BMI , body mass index; DBP, diastolic blood pressure; ExQW, exenatide QW; HDL, high density lipoprotein cholesterol; IG, insulin glargine; Met, metformin; Pio, pioglitazone; Sita, sitagliptin.